approval
saveCYLTEZO (ADALIMUMAB-ADBM) — FDA approval
community read0 votes
Sponsor: BOEHRINGER INGELHEIM. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalOct 16, 2025 · 355d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalMay 20, 2025 · 504d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalApr 30, 2024 · 889d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalJun 30, 2023 · 1194d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalMay 18, 2023 · 1237d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalMar 22, 2023 · 1294d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalOct 3, 2022 · 1464d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalMar 18, 2022 · 1663d ago
same company · ±60 days · 6
- approvalCYLTEZO: CYLTEZO (ADALIMUMAB-ADBM) — FDA approvalJun 30, 2023
- approval(empagliflozin + metformin hydrochloride ER): SYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalJun 20, 2023
- approvalSYNJARDY: JARDIANCE (EMPAGLIFLOZIN) — FDA approvalJun 20, 2023
- approvalSYNJARDY: SYNJARDY (EMPAGLIFLOZIN) — FDA approvalJun 20, 2023
- approvalSYNJARDY: SYNJARDY (EMPAGLIFLOZIN) — FDA approvalJun 20, 2023
- approval(empagliflozin + metformin hydrochloride ER): SYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalJun 20, 2023
comments(0)
5-min edit window · permanent after that